A

AcelRx Pharmaceuticals Inc
F:R5X

Watchlist Manager
AcelRx Pharmaceuticals Inc
F:R5X
Watchlist
Price: 2.106 EUR 9.74%
Market Cap: 310.3m EUR

Relative Value

R5X price has not been updated for more than 1 month. This may indicate that the stock has been delisted.
R5X doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of R5X.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

R5X Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
544.8
Median 5Y
528.7
Industry
2.6
vs History
vs Industry
Median 3Y
-12.7
Median 5Y
-10.4
Industry
21.4
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-16
Industry
16.4
vs History
vs Industry
Median 3Y
-12.6
Median 5Y
-10.9
Industry
22.8
vs History
vs Industry
Median 3Y
18.5
Median 5Y
17.9
Industry
2.2
vs History
vs Industry
Median 3Y
523.2
Median 5Y
507.1
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-16.6
Median 5Y
-16
Industry
13
vs History
vs Industry
Median 3Y
-16.1
Median 5Y
-15.4
Industry
16.5
vs History
vs Industry
Median 3Y
-17
Median 5Y
-15.6
Industry
15.6
vs History
vs Industry
Median 3Y
-16.9
Median 5Y
-15.4
Industry
18.7
vs History
vs Industry
Median 3Y
36.2
Median 5Y
34.6
Industry
1.9

Multiples Across Competitors

R5X Competitors Multiples
AcelRx Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AcelRx Pharmaceuticals Inc
F:R5X
310.3m EUR 585 -13.7 -18.1 -17.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
264.6B CHF 4.3 28 12 14
UK
AstraZeneca PLC
LSE:AZN
220.5B GBP 5.1 31.7 108.8 159.2
CH
Novartis AG
SIX:NOVN
216.5B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.4 10.7 12.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
A
AcelRx Pharmaceuticals Inc
F:R5X
Average P/E: 24.7
Negative Multiple: -13.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
3%
5.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
AcelRx Pharmaceuticals Inc
F:R5X
Average EV/EBITDA: 439.9
Negative Multiple: -18.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
AcelRx Pharmaceuticals Inc
F:R5X
Average EV/EBIT: 1 883.5
Negative Multiple: -17.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5